Clinical Trials

For over 20 years, the Cancer Center at Saint Barnabas Medical Center has been participating in pharmaceutical, cooperative group and investigator initiated clinical trials. Through clinical trials, the Cancer Center is able to offer access to innovative, cutting edge, investigational cancer treatment in order to best serve our patients.

The Cancer Center has partnered with TRIO-US (Translational Research In Oncology-US, Inc.), a not-for-profit clinical research organization, in an effort to expand our clinical trial offerings. The TRIO-US Network has partnered with more than 12 organizations across the country and has now expanded into the Tri-state area for the first time by working with the Cancer Center.

Below is a list of our current clinical trials open for enrollment. For more information on clinical trials or to request more information about an open trial please fill out our clinical trials form or call a member of our research staff at 973-322-2527.

Request For More Information

Current open and enrolling clinical trials:

For more information on the trials please click on the trial name to be directed to the website.

  • Breast

  • S1418
    Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    Lead: Dr. Anna Litvak

  • NSABP-51
    Evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy.
    Lead: Dr. Alison Grann

  • S1207
    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu
    Negative Breast Cancer.
    Lead: Dr. Anna Litvak

  • Sophia / CP-MGAH22-04
    A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
    Lead: Dr. Anna Litvak

  • PUMA-NER-6201
    An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
    Lead: Dr. Miguel Conde

  • NRG-BR003
    A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
    Lead: Dr. Anna Litvak

  • Glioblastoma

  • A071102
    A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
    Lead: Dr. Miguel Conde

  • Lung

  • BMS CA209-817
    A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer
    Lead: Dr. Andrew Brown

  • Multiple Tumor Types

  • CheckMate 627: An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies

  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

[ top ]